Koji Hatsukawa - 18 Mar 2026 Form 3 Insider Report for TAKEDA PHARMACEUTICAL CO LTD (TAK)

Role
Director
Signature
/s/ Max Heuer, by power of attorney, for Koji Hatsukawa
Issuer symbol
TAK
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 06:06:42 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hatsukawa Koji Director 2-27 FUJIMIGAOKA, TSUZUKI-KU, YOKOHAMA, KANAGAWA, JAPAN /s/ Max Heuer, by power of attorney, for Koji Hatsukawa 18 Mar 2026 0002114470

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TAK Ordinary Shares 25,834 18 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TAK Tax Obligation Award 18 Mar 2026 Ordinary Shares 2,152 Direct F2
holding TAK Tax Obligation Award 18 Mar 2026 Ordinary Shares 2,392 Direct F2
holding TAK Tax Obligation Award 18 Mar 2026 Ordinary Shares 2,280 Direct F2
holding TAK Tax Obligation Award 18 Mar 2026 Ordinary Shares 2,318 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an award of 8,600 restricted stock units (RSUs). Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest on the following schedule: June 1, 2026 (2,100 shares), June 1, 2027 (2,200 shares), June 1, 2028 (2,100 shares) and upon retirement from board service (2,200 shares).
F2 Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
F3 Vests upon conclusion of the director's service on the board.

Remarks:

Exhibit 24 Power of Attorney